1.A study on the preparation of a BGN-loaded thermosensitive adhesive and its performance in barrier membrane fixation
WANG Yuzhu ; GU Junting ; LI Zhiting ; BAI Que ; DANG Gaopeng ; WANG Yifei ; SUN Xiaotang ; NIU Lina ; FANG Ming
Journal of Prevention and Treatment for Stomatological Diseases 2026;34(1):41-53
Objective:
To investigate the barrier membrane fixation performance and enhanced guided bone regeneration (GBR) capability of a thermosensitive adhesive containing bioactive glass nanoparticles in order to provide a novel solution for membrane fixation during GBR procedures.
Methods:
M2NP@BGN (methoxyethyl acrylate-co-N-isopropylacrylamide-co-protocatechuic acid@Bioactive glass nanoparticle), a thermosensitive adhesive, was synthesized via free radical polymerization by compositing methoxyethyl acrylate, N-isopropylacrylamide, and protocatechuic acid into a basic adhesive that was modified with bioactive glass nanoparticle (BGN). The successful fabrication of basic adhesive M2NP was characterized by attenuated total reflection-Fourier transform infrared spectroscopy and nuclear magnetic resonance spectroscopy. The thermosensitive adhesive M2NP@BGN (BGN concentration of 1 mg/mL) was characterized by scanning electron microscopy and a rheometer. By adjusting the BGN concentration (0.1 mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL), the adhesive and mechanical strengths were investigated with a universal testing machine. Biocompatibility was evaluated with a cell counting kit-8 assay and hemolysis test to identify the optimal formulation. The optimal material’s extract was co-cultured with mouse bone marrow mesenchymal stem cells, and its osteogenic activity was examined in vitro by quantitative real-time PCR, alkaline phosphatase, and alizarin red S staining. The rat mandibular defect model was established, filled with bone graft, and divided into 3 groups based on membrane fixation method: M2NP@BGN (BGN concentration of 1 mg/mL) fixation group (M2NP@BGN), titanium nail fixation group (Nail), and unfixed control group (Negative). Bone regeneration was analyzed after 8 weeks by micro computed tomography and histological staining.
Results:
M2NP@BGN (BGN concentration of 1 mg/mL) was successfully synthesized and demonstrated rapid gelation under warm, humid conditions. The adhesive with a BGN concentration of 1 mg/mL exhibited the highest adhesive strength (P < 0.001) and significantly enhanced mechanical strength (P < 0.001) under 37℃ wet conditions. All formulations showed excellent biocompatibility, with cell viability > 80% and hemolysis ratio < 5%. M2NP@BGN (BGN concentration of 1 mg/mL) significantly upregulated the expression of Runx2 and Col I (P < 0.001) and enhanced the activity of osteogenic differentiation markers (P < 0.05). In the animal model, the M2NP@BGN group (BGN concentration of 1 mg/mL) achieved significantly higher bone volume fraction and better bone maturity compared to the negative and nail groups (P < 0.05).
Conclusion
M2NP@BGN (BGN concentration of 1 mg/mL) combines excellent wet adhesion with potent osteogenic activity, enhances the bone augmentation efficacy of membranes, and presents a novel fixation strategy with significant clinical translation potential for GBR therapy.
2.Effects of freeze-drying and dry heat virus inactivation processes on the biological activities of human plasma derived α2-macroglobulin
Teng FENG ; Fangling QI ; Qiang WANG ; Rui WANG ; Shaowei WANG ; Junting JIA ; Chongwei CHEN ; Jingang ZHANG ; Fang YUAN ; Yuyuan MA
Military Medical Sciences 2025;49(1):35-40
Objective To assess the impact of freeze-drying and dry heat virus inactivation processes on the activity ofα2-macroglobulin(A2M)derived from human plasma Cohn fraction Ⅳ.Methods A2M derived from human plasma Cohn fraction Ⅳ was prepared and subjected to programmed freeze-drying with dry heat virus inactivation.The lyophilized products were evaluated for their appearance,water content,and validation of the viral inactivation process.The bioactivity of the products before and after lyophilization as well as before and after dry heat inactivation was determined via trypsin inhibition,and the comparisons were studied.Results The appearance of the lyophilized product was fluffy,and the water content was(5.83±0.45)%.The specific activities of the samples before and after lyophilization were(10.199±0.137)and(10.033±0.201)μg/mg,respectively,with no statistically significantdifference between the two groups(P>0.05).The viral inactivation of the samples was carried out by using dry heat inactivation conditions at 100 ℃ for 30 min.After inactivation,the reduction was ≥5.125 LgTCID50/0.1 mL in Pseudorabies virus(PRV)titers,≥4.500 LgTCID50/0.1 mL in Sindbis virus(SinV)titers,≥6.375 LgTCID50/0.1 mL in encephalomyocarditis virus(EMCV)titers,and≥4.500 LgTCID50/0.1 mL in porcine parvovirus(PPV)titers.The specific activities of the samples before and after dry heat were(9.921±0.292)and(10.091±0.278)μ g/mg,respectively,with no statistically significant difference between the two groups.Conclusion A2M derived from human plasma Cohn fraction Ⅳ,when subjected to freeze-drying followed by dry heat inactivation at 100 ℃ for 30 minutes,can effectively inactivate viruses without altering the biological activity of the product.
3.Research progress in the molecular mechanism of α2-macroglobulin
Fang YUAN ; Junting JIA ; Yuyuan MA
Military Medical Sciences 2025;49(5):396-400
α2-Macroglobulin(A2M)is a high-abundance plasma protein with a molecular weight of 720×103,containing 1451 residues and 11 domains,and was isolated and identified for the first time in 1946.The capture and inhibitory effect on proteases is the classical biological function of A2M.However,A2M can also interact with membrane receptors,cytokines,and growth factors,and act as a molecular chaperone to affect extracellular protein homeostasis so that it is involved in a wide range of physiological and pathological processes such as immunity,inflammation,and degeneration.This article reviews the structural characteristics of A2M,the reported molecular targets,the mechanism of action,and its biological effects in the hope of providing a new line of thought for the functional exploration and clinical applications of A2M.
4.Analysis of the Problems in the Naming of Commercially Available Chinese Patent Medicine in China and Improvement Suggestions Based on the Naming Technical Guidelines for Generic Name of Chinese Patent Medicines
Qi CHEN ; Lei ZHANG ; Jing WU ; Xin LI ; Junting FANG ; Yuqing HE ; Liping LIU
China Pharmacy 2019;30(10):1302-1306
OBJECTIVE: To investigate the situation and existing problems of the naming of commercially available Chinese patent medicine (CPM) in China, and to put forward the improvement suggestions. METHODS: Announced in Dec. 31, 2017 by CFDA, there were totally 169 601 kinds of national coded drugs. Total of 35 513 kinds of CPM with drug approval number “Z” and 68 kinds of imported CPM with importing registration certificates “Z” was screened by using Excel 2013 software. Based on Naming Technical Guidelines for Generic Name of Chinese Patent Medicines (hereinafter referred to as the Guidelines), the unqualified situation of domestic CPM were summarized, and unqualified domestic Chinese patent medicine were analyzed statistically in respects of dosage form, special population medication and area. RESULTS: There were 5 091 kinds of drugs named nonconformity with the “Guidelines”, accounting for 14.34% of domestic CPM. The problems of naming mainly focused on exaggerated naming (1 723 kinds, 33.84%), dosage form un-located after naming (1 118 kinds, 21.96%), naming by endangered protected animals and plants (851 kinds, 16.72%), naming by pharmacology and other related terms (848 kinds, 16.66%). Names emboding “traditional cultural features” (1 324 kinds, 4.35%) took the lower proportion. Top 5 dosage forms of domestic CPM with unqualified naming were tablets (1 203 kinds, 23.63%), capsules (821 kinds, 16.13%), mixture (802 kinds, 15.75%), pills (706 kinds, 13.87%), granules (448 kinds, 8.80%). The problems of special population medication for domestic CPM with unqualified naming concentrated on children’s medication (608 kinds, 11.94%). The main manufacturers of domestic CPM with unqualified naming came from Guangdong (613 kinds, 12.04%), Guangxi Zhuang Autonomous Region (371 kinds, 7.29%), Jilin (265 kinds, 5.21%), Shaanxi (245 kinds, 4.81%) and Beijing (233 kinds, 4.58%). CONCLUSIONS: There are many problems in naming of commercially available domestic CPM in China, mainly reflecting as naming type, dosage form, pediatric drugs, etc. There are fewer names emboding “traditional cultural features”. It is suggested that we should further standardize the naming of CPM by strengthening and perfecting the management and examination system of CPM, highlighting the naming principles of Chinese traditional culture and protecting traditional classical brands.
5.SNP767A/T of FUS2 gene and lung cancer risk in Chinese population.
Xinhua MU ; Kang SHAO ; Cuiyan ZHANG ; Zhaoli CHEN ; Junting WAN ; Kezhi ZHANG ; Ning LI ; Fang ZHOU ; Meihua XIONG ; Jie HE
Chinese Journal of Lung Cancer 2006;9(5):409-412
BACKGROUNDFUS2 gene locating at 3p21.3 is considered a promising candidate tumor suppressor gene. The aim of this study is to examine the difference in FUS2-767A/T polymorphism site between lung cancer patients and normal controls in Chinese population.
METHODSThe genotype FUS2-767A/T was detected in 146 lung cancer patients and 113 normal controls by PCR-SSCP method. The relationship between lung cancer risk and difference in genotypes of FUS2 gene was analysed.
RESULTSFUS2-767A/T was significantly related to histological type (P=0.044), age of the patients with lung cancer (P=0.011) and vessel cancer embolus (P=0.031) in lung cancer group. There was no significant difference in distribution of FUS2 genotypes between lung cancer patients and normal controls (P=0.945).
CONCLUSIONSThe results suggest that the FUS2-767A/T polymorphism may be a susceptibility factor for lung cancer among Chinese population.


Result Analysis
Print
Save
E-mail